论文部分内容阅读
目的 :评价特拉唑嗪、高特灵和哈乐 3种α1 受体阻滞剂治疗前列腺增生症的药物经济学。方法 :对 90例前列腺增生症患者分别应用特拉唑嗪、高特灵和哈乐进行治疗 ,运用药物经济学的费用—疗效分析方法进行评估。结果 :3种药物治疗前列腺增生症疗效各有特点 ,均可明显改善前列腺增生症的主观和客观症状。结论 :特拉唑嗪是治疗前列腺增生症的一种较为经济且安全有效的口服药物。
OBJECTIVE: To evaluate the pharmacoeconomics of telazosin, methotrexate, and halotile 3 blockers in the treatment of benign prostatic hyperplasia. Methods: 90 patients with benign prostatic hyperplasia were treated with terazosin, methotrexate and harlot, respectively. The cost-effectiveness analysis was used to evaluate the method. Results: The efficacy of three kinds of drugs in the treatment of benign prostatic hyperplasia have their own characteristics, which can obviously improve the subjective and objective symptoms of benign prostatic hyperplasia. Conclusion: Terazosin is a more economical and safe oral administration for the treatment of benign prostatic hyperplasia.